^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | rineterkib (LTT462) (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
Excerpt:
An unconfirmed partial response was reported in a pt with cholangiocarcinoma with BRAF mutation...LTT462 is well tolerated. Limited clinical activity was reported with single agent LTT462; best overall response was SD...
DOI:
10.1200/JCO.2020.38.15_suppl.3640
Trial ID:
